Two Phase 3 Studies of the VX-659 Triple Combination Regimen Met Primary Endpoint of Improvement in Lung Function (ppFEV1)

Third Positive Phase 2 Proof-of-Concept Study for VX-150 Further Validates the Potential Role of NaV1.8 Inhibition

The Stories Behind Vertex: 

@vertexpharma